Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Jul 9;15(7):e0235563. doi: 10.1371/journal.pone.0235563

Transmembrane protein western blotting: Impact of sample preparation on detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

Yoshiaki Tsuji 1,*
Editor: Fanis Missirlis2
PMCID: PMC7347119  PMID: 32645092

Abstract

Western blotting has been widely used for investigation of protein expression, posttranslational modifications, and interactions. Because western blotting usually involves heat-denaturation of samples prior to gel loading, clarification of detailed procedures for sample preparation have been omitted or neglected in many publications. We show here the case that even excellent primary antibodies failed to detect a specific protein of interest due to a routine heating practice of protein samples. We performed western blotting for transmembrane iron transporter proteins; SLC11A2 (divalent metal transporter 1, DMT1), SLC40A1 (ferroportin 1, Fpn1), and transferrin receptor-1 (TfR1), along with cytoplasmic iron storage protein ferritin H. Our results in 12 human culture cell lysates indicated that only unheated samples prior to gel loading gave rise to clear resolution of DMT1 protein, while heated samples (95°C, 5min) caused the loss of resolution due to DMT1 protein aggregates. Unheated samples also resulted in better resolution for Fpn1 and TfR1 western blots. Conversely, only heated samples allowed to detect ferritin H, otherwise ferritin polymers failed to get into the gel. Neither different lysis/sample loading buffers nor sonication improved the resolution of DMT1 and Fpn1 western blots. Thus, heating samples most critically affected the outcome of western blotting, suggesting the similar cases for thousands of other transmembrane and heat-sensitive proteins.

Introduction

More than 3,000 human genes encode transmembrane proteins that have been classified into receptors, transporters, enzymes, and other proteins [1]. Transmembrane proteins such as solute carrier (SLC) transporters play vital roles in import and export of nutrients, metabolites, and ions. Examples of SLC substrates are sugars, amino acids, vitamins, neurotransmitters, urea cycle metabolites, and metals [2, 3] including iron [4]. The human SLC transporter families comprise more than 400 genes and 52 subfamilies under the SLC family clusters, including MFS (major facilitator superfamily) and APC (amino acid-polyamine-organocation) superfamily [3, 5, 6]. The majority of SLC transporter proteins has 12-transmembrane segment (TMS) with diversities typically ranging from 9 to 14 TMS [7].

Iron metabolism is coordinately regulated by iron import, export, and storage proteins localized in plasma membrane and intracellular compartments [810]. For instance, human transferrin receptor-1 (TfR1) is an 85 KDa homodimer of a plasma single-transmembrane protein serving as a major iron importing receptor for transferrin bound to two molecules of ferric iron (Fe3+) [11, 12]. Iron is also subject to import and export by SLC transmembrane transporters. One is SLC11A1 and A2; particularly SLC11A2 (Divalent Metal Transporter—DMT1 or NRAMP2) which is a ubiquitously expressed transporter of iron along with cadmium, cobalt, manganese, and zinc to a lesser extent [1315]. DMT1 plays a pivotal role in apical iron (Fe2+) absorption (after Fe3+ is reduced by ferric reductase DcytB, [16]) into duodenal enterocytes [13, 17, 18]. DMT1 also transports endosomal iron released from transferrin (and reduced by Steap3) into the cytoplasm for supply of ferrous iron (Fe2+) in various cell types [8]. The DMT1 gene encodes four isoforms of mRNAs through alternative promoter and splicing [17, 19, 20], giving rise to at least four different DMT1 proteins [19]. The four isoforms of human DMT1 are 61–65 KDa transmembrane proteins having 12-TMS [13, 15, 21]. Another SLC protein in charge of iron export is SLC40A1 (Ferroportin 1—Fpn1 or IREG1) that is highly expressed in basolateral membrane of duodenal enterocytes and exports iron into blood stream [2224], where Fe2+ is oxidized to Fe3+ by membrane-bound hephaestin or ceruloplasmin circulating in blood stream, transferring Fe3+ to transferrin for systemic delivery of iron (Fe3+) [25]. Fpn1 is also highly expressed in reticuloendothelial macrophages that release iron for recycling after erythrophagocytosis [26, 27]. Fpn1 is a 63 kDa multipass transmembrane protein predicted to contain 12-TMS [28, 29]. Hepcidin, a 25-amino acid peptide secreted from the liver in response to iron overload and inflammation [3032], binds and induces internalization and degradation of Fpn1 leading to decrease in plasma iron levels and iron distribution to tissues [33]. When Fe2+ levels are more than what cells need, the surplus of iron is stored into ferritin shell composed of 24 multi-subunits of tissue-specific ratios of H (heavy) and L (light) chains [11, 34, 35]. Iron (Fe2+) is stored in ferritin shell as Fe3+ catalyzed by the ferroxidase activity of the ferritin H subunit [34].

Western blotting is an important technique to investigate protein expression, posttranslational modifications (e.g. phosphorylation), and interactions with other proteins and macromolecules, in which we mostly use commercially available antibodies for detection of proteins of our interests. There are numerous monoclonal and polyclonal antibodies successfully used for western blotting and other applications (CiteAb, https://www.citeab.com/), while we still experience antibodies not working or far below our expectation of qualities for unknown reasons. To verify the quality and specificity of antibodies, we should take positive and negative control samples such as cell lysates prepared after transient transfection of expression plasmids or knockdown of endogenous mRNAs. In particular, detection of transmembrane proteins in western blotting has often been challenging due to difficulties in solubilization of those proteins with detergents and reducing agents. There are numerous numbers of transmembrane protein western blots so far published, including DMT1 and Fpn1 proteins (CiteAb). In this report, we initially judged our DMT1 and Fpn1 antibodies not working in our routine western blotting protocol; however, reassessment and modification of our protocol in a sample preparation step significantly improved the resolution of western blots.

Materials and methods

Cell culture and maintenance

12 human cell lines used in this study and their culture media are listed in Table 1. All cell lines were cultured at 37°C in a humidified CO2 incubator (5% CO2, Sanyo model MCO-17AIC). Undifferentiated Caco-2 cells were used in this study. Adherent cells were passaged by trypsinization (0.25% Trypsin, 2.6 mM EDTA in calcium/magnesium free PBS) every 3–5 days when they were confluent. Suspension cells were passaged by 20~30-fold dilution to fresh growth media every 4–6 days.

Table 1. All chemicals and reagents used in this study.

REAGENT OR RESOURCE SOURCE IDENTIFIER (catalog #)
Antibodies
Mouse monoclonal anti-ferritin H Santa Cruz Biotechnology sc-135667 (3F8)
Rabbit polyclonal anti-transferrin receptor Abcam ab84036
Rabbit monoclonal anti-DMT1/SLC11A2 Cell Signaling Technology 15083 (D3V8G)
Rabbit polyclonal anti-ferroportin 1(SLC40A1) Novus Biologicals NBP1-21502
Mouse monoclonal anti-GAPDH Chemicon MAB374
Mouse monoclonal anti-Flag Sigma-Aldrich F3165
Goat anti-mouse IgG-peroxidase conjugated Millipore AP181P
Goat anti-rabbit IgG-peroxidase conjugated Millipore AP132P
Chemicals/Culture Media
Dulbecco's modified Eagle Medium (DMEM) Corning 50-003-PC
Minimum Essential Medium (MEM) Corning 50-011-PC
RPMI1640 Corning 50-020-PC
Ham's F12 Corning 50-040-PB
Opti-MEM Life Technologies 22600–134
Penicillin Streptomycin solution, 100X Corning 30-002-CI
Sodium pyruvate Corning MT25000CI
Non-essential amino acid solution, 100X Corning 25-025-CI
Trypsin, 10X Corning 25-054-CI
Fetal Bovine Serum Seradigm 1400–500
Ammonium iron(III) citrate (FAC) Sigma-Aldrich F5879
Deferoxamine mesylate salt (DFO) Sigma-Aldrich D9533
Hemin Fluka 51280
Acrylamide J.T. Baker 4081–01
Bis-Acrylamide EMD Millipore 2620
Sodium dodecyl sulfate (SDS) Calbiochem 7910
Sodium deoxycholate Sigma-Aldrich D-6750
Nonidet-P40 (NP40) US Biological N-3500
Tris (Hydroxymethyl) Aminomethane J.T. Baker 4109–06
Glycine J.T. Baker 4057–06
Sodium chloride BDH 7647-14-5
Ammonium persulfate Thermo Scientific 17874
TEMED Fisher BP150-100
Skim milk powder EMD Millipore 1.15363.0500
Bovine Serum Albumin (BSA) Fraction V EMD Millipore (Calbiochem) 2930
Tween 20 Fisher BP337-500
2-mercaptoethanol EMD Millipore 6050
Glycerol Fisher BP229-1
Bromophenol blue Sigma-Aldrich B-8026
Hepcidin Peptide Institute, Inc. PLP-4392-s
HyGLO Chemiluminescent HRP Detection Reagent Denville Scientific E2500
Pierce ECL Western Blotting substrate Thermo Scientific 32106
Clarity Western ECL Substrate Bio-Rad 170–5061
Protein Assay Dye Reagent Concentrate Bio-Rad 5000006
Precision Plus Protein Dual Color Standards Bio-Rad 161–0374
Protease Inhibitor Cocktail Set I Calbiochem/Millipore 539131
Transmembrane Protein Extraction Reagent FIVEphoton Biochemicals TmPER-50
Nco I New England Biolabs R0193S
Hind III New England Biolabs R0104S
SmaI New England Biolabs R0141S
DNA polymerase Klnenow fragment New England Biolabs M0210L
Lipofectamine RNAiMax Invitrogen 13778–150
Cell lines Source/Culture Media(containing 1x Penicillin Streptomycin)
HaCaT immortalized human keratinocyte NE Fusenig/ DMEM high glucose (4.5g/L) +10%FBS Boukamp et. al J. Cell Biol., 106: 761–771 (1988)
HepG2 human hepatocellular carcinoma ATCC/ MEM +10% FBS HB-8065
HEK293 immortalized human embryonic kidney cells ATCC/ MEM +10% FBS CRL-1573
HeLa human cervix adenocarcinoma ATCC/ MEM +10% FBS CCL-2
K562 human erythroleukemia ATCC/ RPMI1640, 25 mM HEPES +10%FBS CCL-243
SW480 human colon adenocarcinoma ATCC/ DMEM high glucose (4.5g/L) +10%FBS CCL-228
A549 human lung carcinoma Sigma-Aldrich/ DMEM high glucose +10%FBS 86012804
HL60 human promyelocytic leukemia ATCC/ RPMI1640, 25 mM HEPES +10%FBS CCL-240
MCF7 human breast adenocarcinoma ATCC/ MEM +10% FBS HTB-22
SH-SY5Y human neuroblastoma ATCC/ MEM:Ham's F12(1:1) +10% FBS CRL-2266
Jurkat human acute T cell leukemia, clone E6-1 ATCC/ RPMI1640, 25 mM HEPES, high glucose +10%FBS TIB-152
Caco-2 human colorectal carcinoma ATCC/ MEM +20%FBS HTB-37
plasmid DNA
pCMVSPORT6 SLC40A1 Dharmacon MHS6278-202801506
pBluescriptR SLC11A2(DMT1) Open Biosystems MHS1010-98075408
pRK5SLC11A2(DMT1) this work
pCMVFlagSLC40A1(DMT1) this work

Chemicals, and reagents

All chemicals and reagents used in this study, their suppliers, and catalog numbers are listed in Table 1. Ferric ammonium citrate (FAC) and desferrioxamine (DFO) were dissolved in distilled water at 100mM and 25mM, respectively. Hemin was dissolved in 0.1M NaOH at 50mM. Human bioactive hepcidin was dissolved in water at 0.5mM, added to undifferentiated Caco-2 culture at 0.5uM, and incubated for 18–24 hr.

Western blot and antibodies

Whole cell lysates (WCLs) were prepared from sub-confluent or confluent cells grown in 60 mm culture plates (Greiner, 628160). In some experiments, cells were treated with FAC, DFO, or hemin for 18–24 hr before harvest. Cells were washed with phosphate buffered saline (PBS: 137mM NaCl, 27mM KCl, 15mM KH2PO4, 81mM Na2HPO4) and lysed in 200-400ul of PBS-based RIPA buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing 1X protease inhibitor cocktail (Calbiochem/Millipore). In Fig 2, we also prepared HEK293 WCL in RIPA buffer sonicated for 10 sec. three times in ice-water (550 Sonic Dismembrator, Fisher) or WCL in transmembrane extraction reagent (Five Photon Biochemicals). We did not centrifuge WCLs to remove DNA or debris. Protein concentrations in WCLs were measured with 1X Bio-Rad protein assay dye reagent. 15–30 ug of WCLs were mixed with 2X SDS-PAGE (polyacrylamide gel electrophoresis) sample buffer containing 62.5mM Tris-HCl (pH 6.8), 25% Glycerol, 2% SDS, 0.01% bromophenol blue, and 5% β-mercaptoethanol. The volume of 2X SDS-PAGE sample buffer was equal or more than varied WCL volumes for an equal amount of total proteins. For preparation of heated and non-heated samples, one group was heated at 95°C for 5min in a dry bath incubator (11-718-2, Fisher) containing water in a heating block, while another group was left at room temperature. After briefly spinning down sample tubes, WCLs were loaded on 10% SDS-PAGE (10% acrylamide, 0.27% bisacrylamide, 375mM Tris-HCl pH 8.8, and 0.1% SDS) mini-gel (4x2.9 inches). The stacking gel was 5% acrylamide containing 0.13% bisacrylamide, 125mM Tris-HCl pH 6.8, and 0.1% SDS. Protein size markers (Bio-Rad Precision Plus Protein Standards) was loaded without heating. The electrophoresis was run at 12.5mA per mini-gel for approximately 1.5hr in the running buffer containing 25mM Tris, 192mM Glycine, and 0.1% SDS. Proteins separated on the gel were transferred to PVDF membrane (Thermo Scientific, 88518) in a mini trans-blot cell (Bio-Rad, 022711PM) at 300mA in a transfer buffer (25mM Tris pH 8.3, 192mM Glycine, and 20% methanol) at 4°C for 1.5–2hr. The PVDF membrane was blocked for 20-30min at room temperature in either 1% BSA or 5% skim milk dissolved in 0.1% Tween 20-containing Tris-buffered saline (TBS: 20mM Tris-HCl pH 7.6 and 137mM NaCl) and incubated with a primary antibody on a rocker platform (Speci-Mix, Thermolyne) at 4°C overnight. The primary antibodies for western blots listed in Table 1 were diluted with either 5% skim milk in 0.1% Tween/TBS for anti-ferritin H (1:1,000), anti-TfR1 (1:20,000), anti-DMT1/SLC11A2 (1:1,000), anti-GAPDH (1:5,000), anti-Flag (1:1,500), or 1% BSA in 0.1% Tween/TBS for anti-Fpn1/SLC40A1 (1:1,000~1,500). The PVDF membranes were washed with approximately 50 ml of 0.1% Tween/TBS for 10-20min, three times at room temperature, and incubated with a secondary antibody as listed in Table 1 (5,000–8,000-fold diluted with the same dilution solution as a primary antibody, either 5% skim milk or 1% BSA in 0.1% Tween/TBS) for 1.5hr at room temperature. The PVDF membranes were washed with 0.1% Tween/TBS three times, incubated with ECL reagents (Table 1) at room temperature, and exposed to X-ray films (ProSignal Blotting Film, Genesee Scientific 30-507L or 30-810L). For successive incubation with another primary antibody, the membrane was soaked at room temperature for 1 hr in the stripping solution (pH 2.2 with HCl) containing 1.5% glycine, 0.1% SDS, and 1% Tween 20 (from Abcam’s western blot membrane stripping for restaining protocol). After washing membrane in 0.1% T/TBS for 15min three times, the procedure was repeated from blocking the membrane with 1% BSA or 5% skim milk in 0.1% T/TBS.

Fig 2. Comparison in Fpn1 (SLC40A1) western blotting between heated and unheated protein samples from Fpn1 transfected cells.

Fig 2

A) WCL in RIPA buffer was prepared from HEK293 cells transfected with pCMV or pCVMFpn1. 25ug of the WCL mixed with 2X SDSPAGE sample loading buffer was heated at 95°C for 5min and subjected to Fpn1 western blotting. The arrow indicates the Fpn1 protein stuck on the top of the separation gel (also in B and C). B) WCL in RIPA buffer, in RIPA plus sonication for 10 seconds three times in ice-water, or in transmembrane protein extraction reagent (Five Photon Biochemicals) was prepared from HEK293 cells transfected with pCMV or pCVMFpn1(6ug, *Fpn1: 12ug DNA). 15ug of the WCLs mixed with 2X SDSPAGE sample loading buffer were heated at 95°C for 5min or not heated (at room temperature), and subjected to Fpn1 western blotting. The arrowhead indicates the transfected Fpn1 band. C) WCLs in RIPA buffer from HEK293 cells transfected with pCMV or pCVMFpn1 were mixed with 2X SDSPAGE sample loading buffer containing 5% β-mercaptoethanol (regular), 4M urea, or both 5% β-mercaptoethanol and 4M urea. One sample set was heated at 95°C 5min, another set was not heated (at room temperature), and subjected to Fpn1 western blotting. Positions of molecular weight protein size marker are indicated on the left. The experiments were repeated three times and the representative western blots are shown.

Isolation of cytoplasmic and nuclear fractions

Cells were washed with PBS, resuspended in 200-500ul hypotonic buffer (20mM Tris-HCl, pH 7.4, 10mM NaCl, 3mM MgCl2) at 4°C for 15min, then mixed with 1/20 volume of 10% NP40, vortexed for 10 sec, and centrifuged at 12,000 rpm for 30 sec. The supernatant was recovered (cytoplasmic fraction), and the pellet was resuspended in 30-50ul of extraction buffer containing 100mM Tris, pH 7.4, 2mM Na3VO4, 100mM NaCl, 1% Triton X-100, 1mM EDTA, 10% glycerol, 1mM EGTA, 0.1% SDS, 1mM NaF, 0.5% deoxycholate, 20mM Na4P2O7, and 1X proteinase inhibitor cocktail. The pellet suspension was vortexed for 10 sec, incubated on ice for more than 30min, vortexed for 30 sec, and centrifuged at 12,000 rpm for 10min at 4°C. The supernatant (nuclear fraction) was recovered.

Plasmids, siRNA, and transfection

pCMVSport6Fpn1 (MGC human SLC40A1 sequence-verified cDNA, clone ID: 5213437, MHS6278-202801506) was purchased from GE Dharmacon. pBluescriptR-DMT1 (SLC11A2 MGC human clone ID: 5300266, MHS1010-98075408) was purchased from Open Biosystems. The 2.5kb DMT1 cDNA was isolated after digestion with NcoI and HindIII followed by filling-in with DNA pol. Klenow fragment, and cloned into SmaI site of pCMV and pCMVFlag vectors. These plasmid DNAs, verified by DNA sequencing (Eurofins), were transiently transfected into HEK293 cells by electroporation (X-Cell, Bio-Rad) as described previously [36].

Human Fpn1 siRNA was purchased from Sigma-Aldrich (GAUGGAACUUGGUAUCCAU[dT][dT], and AUGGAUACCAAGUUCCAUC[dT][dT]) and 5ul of 20uM solution was transfected into Caco-2 cells (grown in 2ml media/35 mm plate) with 200ul of Opti-MEM containing 6ul of Lipofectamine RNAiMax (Invitrogen) for 18hr, followed by treatment with 250 and 500uM FAC for additional 8hr in the presence of siRNA prior to harvest. Knockdown of Fpn1 in Caco-2 cells was first verified by qPCR as described previously [37] using three sets of human Fpn1 primers.

  • Set1 forward: 5’-CTACTTGGGGAGATCGGATGT-3’

  • Set1 reverse: 5’-CTGGGCCACTTTAAGTCTAGC-3’

  • Set2 forward: 5’-TGGATGGGTTCTCACTTCCTG-3’

  • Set2 reverse: 5’-GTCAATCCTTCGTATTGTGGCAT-3’

  • Set3 QuantiTect Primer Assays for Hs_SLC40A1 (QT00094843, Qiagen)

Results

Routine practice of heating samples in Fpn1 (SLC40A1) western blot

According to the citation history for Fpn1 antibody in CiteAb, the rabbit polyclonal anti-Fpn1 antibody NBP1-21502 (Novus Biologicals) has been most successfully used in research article publications (https://www.citeab.com/). After preliminary testing of optimum dilutions of this primary antibody with either 5% skim milk or 1% BSA in Tween/TBS buffer, we decided to use 1,000–1,500-fold dilution in 1% BSA in Tween/TBS. We prepared WCL samples from several culture cell lines, heated at 95°C for 5min, loaded on a 10% acrylamide SDS-PAGE gel, and performed western blotting. The blot gave rise to multiple bands including the putative Fpn1 band* (63 kDa) between 50 and 75 kDa size markers (Fig 1A).

Fig 1. Heated samples for Fpn1 (SLC40A1) western blotting.

Fig 1

A) 25ug of whole cell lysates (WCLs) prepared from indicated cells (*two different preparations of SW480 WCLs) were subjected to Fpn1 western blotting as detailed in the Materials and Methods. This experiment used sample loading buffer containing 5% β-mercaptoethanol, heated at 95°C for 5 min, anti-Fpn1 antibody (Novus, rabbit polyclonal, 1,000-fold diluted with 1% BSA in T/TBS) at 4°C overnight followed by anti-rabbit IgG-HRP conjugated (8,000-fold diluted with 1% BSA in T/TBS) at room temperature for 1.5hr. Unless otherwise noted, the rest of western blots in this study were performed in the same procedures with or without sample heating prior to gel loading. B) SW480 cells were treated with 0.1–0.5mM FAC (ferric ammonium citrate), 2-100ug/ml cisplatin, or FAC 0.25mM plus cisplatin 10ug/ml for 18hr. 20ug of WCLs were subjected to Western blotting with anti-Fpn1 antibody (top). The membrane was soaked in the stripping solution at room temperature for 1hr, washed with T/TBS, and incubated with anti-ferritin H mouse monoclonal antibody (sc-135667, Santa Cruz Biotechnology). In A) and B), the asterisks indicate the predicted position (63 kDa) of the endogenous Fpn1. The experiments were repeated three times and the representative western blots are shown.

The expression of Fpn1 can be increased by high iron levels through dissociation of IRE-binding protein 1 and 2 (IRP1 and IRP2) from the iron-responsive element (IRE) in 5’-UTR of Fpn1 mRNA [22]. Additionally, another Fpn1 mRNA (termed FPN1B) transcribed from an alternative promoter lacks the IRE but has the same open reading frame, therefore FPN1B expression is not responsive to cellular iron status [38]. To characterize the putative Fpn1 band further, we treated SW480 cells with ferric ammonium citrate (FAC) or cisplatin that directly inhibits IRP2 binding to IRE [39] and performed western blotting. The putative 63 kDa faint band was not increased by FAC but slightly increased by cisplatin treatment in SW480 cells (Fig 1B). In contrast, ferritin H was significantly increased by FAC and cisplatin because ferritin H mRNA also contains a functional 5’-IRE [40, 41], suggesting that FAC and cisplatin treatments are working to drive 5’-IRE-dependent translational upregulation. Collectively, we demonstrate that the most popular anti-Fpn1 antibody gave rise to the band around 63 kDa but it did not show clear regulation through the IRP-IRE system in SW480 cells. Thus, without taking a positive control for western blotting, the identity of the 63 kDa band in Fig 1 remained undetermined.

No solubilization problem but heating samples may compromise Fpn1 western blot

To validate the putative Fpn1 band and anti-Fpn1 antibody further, we made WCL from HEK293 cells transiently transfected with a human Fpn1 expression plasmid and performed western blotting in a routine sample preparation and heating protocol (see Materials and Methods). The overexpressed Fpn1 (untagged) gave rise to one specific band that was stuck on the top of the separation gel (Fig 2A).

This result indicates that the Fpn1 antibody (NBP1-21502, Novus Biologicals) can detect at least overexpressed human Fpn1 protein by western blotting, in which the Fpn1 protein appeared to be insolubilized or aggregated. To solve the potential solubilization problem first, we used three different cell lysis conditions; RIPA lysis buffer, RIPA plus sonication, and transmembrane extraction reagent (Five Photon Biochemicals). To solve the aggregation problem, we compared heated samples at 95°C to no heating (room temperature) of WCL from HEK293 transfected with pCMV-empty or -Fpn1 plasmid. As shown in Fig 2B, regardless of three different lysis conditions, transfected Fpn1 was stuck on the top of the gel when they were heated at 95°C prior to gel loading. In contrast, no heating samples gave rise to a specific Fpn1 band between 50 and 75kDa markers regardless of their different lysis conditions (Fig 2B). Furthermore, HEK293 WCL in RIPA mixed with three different 2X SDSPAGE sample loading buffers containing 5% β-mercaptoethanol (the regular sample loading buffer, see Materials and Methods), 4M urea, or both 5% β-mercaptoethanol and 4M urea did not improve the migration problem of overexpressed Fpn1 protein when they were heated (Fig 2C). By contrast, no heating of these WCL samples showed the right size of Fpn1 band regardless of the use of different loading buffers (Fig 2C). Taken together, we concluded that no heating of protein samples is the most critical factor for the right resolution and detection of transfected Fpn1 protein by western blotting with this anti-Fpn1 polyclonal antibody.

Heating samples compromised DMT1 (SLC11A2) western blot

Another key SLC protein handling cellular iron traffic is DMT1 (SLC11A2). According to the citation data in CiteAb, there are more than 10 different anti-DMT1 antibodies used for publications. Among them, we used a rabbit monoclonal anti-DMT1 antibody (D3V8G, Cell Signaling Technology). To test whether heating protein samples also affects the resolution of DMT1 western blots, we prepared WCLs in RIPA or cytoplasmic and nuclear fractions from HEK293 cells transiently transfected with human DMT1 (untagged) or Flag-DMT1. Samples were mixed with 2x SDSPAGE sample loading buffer (containing 5% β-mercaptoethanol), heated at 95°C for 5min or left at room temperature, and performed SDS-PAGE and western blotting with anti-DMT1 or Flag antibody. As observed in the Fpn1 western blots in Fig 2, heating protein samples significantly impaired the DMT1 protein bands (Fig 3A). In clear contrast, no heating of samples (left at room temperature until sample loading) showed good resolution of ~75kDa and additional larger and smaller bands detected with anti-Flag (Fig 3A, top) as well as anti-DMT1 antibodies (Fig 3A, bottom). DMT1 mRNA isoforms contain 3’-UTR IRE [42] that should be subject to mRNA destabilization when IRP1 and/or IRP2 dissociates from the IRE in iron overloaded conditions or by inactivation of IRP2 following cisplatin treatment [39]. Indeed, endogenous DMT1 proteins were detected by western blotting in unheated WCLs isolated from SW480 cells treated with FAC (0.1–0.5 mM) or cisplatin (2–100 ug/ml), in which FAC or cisplatin treatment slightly decreased DMT1 protein levels (Fig 3B). Collectively, no heating of protein samples prior to loading to SDS-PAGE gel is critical for detection of transfected and endogenous DMT1 proteins by western blotting.

Fig 3. Comparison in DMT1 (SLC11A2) western blotting between heated and unheated protein samples.

Fig 3

A) WCL in RIPA buffer, or cytoplasmic (Cyto) and nuclear (Nuc) fractions were prepared from HEK293 cells transfected with pCMVFlag, pCMVDMT1 or pCVMFlagDMT1. 30ug of the WCL, Cyto, and Nuc fractions mixed with 2X SDSPAGE sample loading buffer were heated at 95°C for 5min or not heated (at room temperature), and subjected to western blotting with anti-Flag antibody (top) or anti-DMT1 antibody (bottom). B) WCLs in RIPA buffer were prepared from SW480 cells treated with 0.1–0.5mM FAC (ferric ammonium citrate), 2-100ug/ml cisplatin, or FAC 0.25mM plus cisplatin 10ug/ml for 18hr. 20ug of WCLs mixed with 2X SDSPAGE sample loading buffer without heating were subjected to Western blotting with anti-DMT1 antibody (top: longer exposure, bottom: shorter exposure). As a control, heated or unheated WCL from pCMVDMT1-transfected HEK293 cells was loaded. The experiments were repeated four times and the representative western blots are shown.

Effects of heating samples from 12 human cell lines on DMT1 and Fpn1 western blots

To assess the effect of heating samples on detection of endogenous DMT1 and Fpn1 proteins in various cell types by western blotting, we prepared WCLs from 12 human cell lines (lysed in RIPA), mixed with 2x SDSPAGE sample loading buffer, heated at 95°C for 5min or not heated (left at room temperature), and performed SDSPAGE and Western blotting. Given the results of transfected Fpn1 and DMT1 in Figs 2 and 3, only unheated WCLs from HEK293 cells transfected with empty vector, DMT1, and Fpn1 were loaded together as positive controls of western blots. As shown in Fig 4A, endogenous DMT1 proteins were detected in most of these human cell lines; however, heating samples at 95°C for 5min reproducibly impaired the major DMT1 band, some of which were stuck on the top of the gel (arrow on the right). Fpn1 western blots were more complicated because of multiple major bands in addition to no clear difference between heated and unheated samples (Fig 4B). This was an unexpected result because transiently transfected Fpn1 protein in HEK293 cells was detected only when the samples were not heated prior to loading to SDSPAGE gel (Fig 2). The Fpn1 western blotting was working in Fig 4B because transiently transfected Fpn1 used as a positive control was detected in the range between 50 and 75kDa size markers (Fig 4B). The endogenous protein showing the same migration as transfected Fpn1 was also detected in several cell types such as Caco-2 cells (Fig 4B).

Fig 4. Comparison in DMT1 and Fpn1 western blotting between heated and unheated protein samples from 12 human cell lines.

Fig 4

25ug of WCLs in RIPA buffer from indicated 12 human cell lines were mixed with 2X SDSPAGE sample loading buffer, either heated at 95°C for 5min or not heated (at room temperature), and subjected to A) DMT1 and B) Fpn1 western blotting. As a control, 10ug of non-heated WCL from HEK293 cells transfected with pCMV, pCMVDMT1, or pCMVFpn1 was loaded. The arrowheads indicate the positions of transfected DMT1 and Fpn1 bands. In A), the arrow indicates the DMT1 protein stuck on the top of the separation gel. The experiments were repeated four times and the representative western blots are shown.

As our Fpn1 western blots gave rise to multiple non-specific bands, we further verified the endogenous band migrating together with transfected Fpn1. First, transfection of Fpn1 siRNA into undifferentiated Caco-2 cells reduced Fpn1 mRNA level to 35.3% (p = 0.007 in unpaired t-test, FAC 0) and consistently diminished the endogenous protein band co-migrating with transfected Fpn1 (Fig 5A). Second, as hepcidin binds Fpn1 and induces Fpn1 internalization and degradation [43] in Caco-2 cells [44], we treated Caco-2 cells (3 plates each) with bioactive hepcidin at 500 ng/ml for 24hr and performed Fpn1 western blotting, in which hepcidin-treated cells appeared to have decreased Fpn1 protein levels (Fig 5B). Collectively, we concluded that the band co-migrating with transfected Fpn1 is the endogenous Fpn1 protein.

Fig 5. Verification of the band specific to endogenous Fpn1 protein.

Fig 5

A) Caco-2 cells were transfected with Control- or Fpn1-siRNA using Lipofectamine RNAiMax for 18hr, followed by treatment with FAC at the final 250 and 500uM for additional 8hr in the presence of siRNA. Unheated Caco-2 WCLs in RIPA buffer along with unheated WCL from HEK293 cells transfected with pCMV or pCVMFpn1 were analyzed by western blotting for Fpn1 (top) followed by incubation with anti-GAPDH antibody. B) Caco-2 cells were untreated or treated with 500nM hepcidin (3 plates each) for 22h. 20ug of three-independent hepcidin (-) and hepcidin (+) WCLs in RIPA buffer were mixed with 2X SDSPAGE sample loading buffer, unheated, and subjected to Western blotting with the anti-Fpn1 antibody. Unheated WCL from HEK293 cells transfected with pCMV or pCVMFpn1 was loaded as a control. The membrane was incubated with the anti-GAPDH antibody to assess an equal amount of sample loading. The experiments were repeated five times and the representative western blots are shown.

Effects of heating samples for single-transmembrane TfR1 and cytoplasmic ferritin western blots

We elucidated the effect of sample heating on western blots for two other key iron transport and storage proteins; single-transmembrane TfR1 and cytoplasmic ferritin. We prepared WCL in RIPA from Caco-2 cells treated with hemin, FAC, and an iron chelator deferoxamine (DFO) for 24hr. We compared heated samples with unheated samples for detection of each endogenous protein by western blotting. In Fpn1 western blotting, transiently transfected Fpn1 in HEK293 was reproducibly detected in unheated samples, whereas heated samples failed to show the right size of Fpn1 band between 50-75kDa protein size markers, rather showing very faint bands stuck on the top of the gel (arrow, Fig 6A right). FAC or hemin treatment in Caco-2 cells increased a band migrating similar to transfected Fpn1, in which the unheated group of samples showed slightly stronger bands compared to heated samples at 95°C for 5min (Fig 6A).

Fig 6. Comparison in western blotting for ferritin and TfR1 proteins between heated and unheated samples from Caco-2 cells treated with iron.

Fig 6

Caco-2 cells were untreated or treated with 50uM hemin, 250 and 500uM FAC, or 25uM DFO for 24hr. 25ug of Caco-2 WCLs along with 10ug of WCL from HEK293 cells transfected with pCMV or pCVMFpn1 were heated at 95°C for 5min or not heated (at room temperature). They were subjected to successive western blotting with A) anti-Fpn1 (SLC40A1), B) anti-DMT1 (SLC11A2), C) anti-ferritin H, D) anti-TfR1, and E) anti-GAPDH antibodies. The larger area of Fpn1 western blot for HEK293 cells transfected with pCMV or pCVMFpn1 is shown right next to the panel A. The arrow indicates the transfected Fpn1 protein stuck on the top of the separation gel. The asterisk in D) may be a TfR1 dimer only seen in unheated samples. The experiments were repeated three times and the representative western blots are shown. The same experiment repeated in HepG2 cells are shown in S2 Fig.

Conversely, we anticipated that the iron chelator DFO would inhibit translation of Fpn1 mRNA via the 5’-UTR IRE; however, we repeatedly failed to observe it (Fig 5A, DFO compared to none). The endogenous DMT1 was consistently detected only when samples were not heated (Fig 6B). In contrast, the H subunit of ferritin (ferritin H) was detected as increased by hemin or FAC treatment only in heated samples (Fig 6C). As ferritin is composed of 24 subunits of ferritin H and L, heat denaturation of samples is necessary for ferritin western blot otherwise we often observed no ferritin bands or ferritin stuck on the top of the gel (S1 Fig). Interestingly, western blot for an 85 KDa homodimer of a plasma single-transmembrane protein TfR1 showed that unheated samples gave much stronger bands in an iron-responsive manner (iron-mediated downregulation) than samples heated at 95°C for 5min (Fig 6D). The unheated samples gave rise to an additional higher molecular weight band, probably a dimer of TfR1, in an iron-responsive manner (asterisk in Fig 6D). The cytoplasmic protein GAPDH as a protein loading control was detected equally in both heated and unheated samples (Fig 6E). Similar results were observed in HepG2 WCLs except for the endogenous Fpn1 band showing no clear differences between heated and unheated samples, both of which showed clear iron-induced Fpn1 expression following FAC treatment (S2 Fig).

Discussion

Western blotting techniques were improved and seemingly have established, which may make us often omit in publications describing critical steps and tips for detection of protein of interest in western blotting. This is partly because a standard protocol for sample preparation has a routine protein denaturation step by heating at 95–100°C in a sample loading buffer containing SDS and a reducing agent such as β-mercaptoethanol or dithiothreitol. This heating step is understood important for antibodies to find epitopes efficiently as well as to detect a specific protein in multiple protein binding complexes or a subunit of multimeric proteins as exemplified by the detection of ferritin in this study (Fig 6C). However, detection of transmembrane proteins by western blotting seems to be more challenging and complicated. There are more than 3,000 human genes encoding transmembrane proteins, in which ~ 1,300 receptors including seven-transmembrane GPCR (G protein coupled receptor) and single-pass transmembrane receptors, ~ 800 transporters such as SLC, ABC (ATP binding cassette) transporters, and channels, and ~ 500 enzymes including transferases, hydrolases, and oxidoreductases [1]. We sometimes find researcher’s troubleshooting discussions via internet medias about unsuccessful western blotting for detection of particular transmembrane proteins. Along with our initial failure to detect SLC family iron transporters in this study, we anticipate that routine heat denaturing protocols may not work or significantly loose band signals in western blotting to detect many more transmembrane and heat-sensitive proteins, perhaps due to heat-induced protein aggregations and/or conformational changes.

In this study, we observed that non-heated samples solely solved the migration and resolution problems of DMT1 and overexpressed Fpn1 western blots, whereas three different cell lysis conditions or three different 2X sample loading buffers did not improve the situation (Fig 2). Despite the fact that both DMT1 and Fpn1 are 12-transmembrane proteins [13, 15, 28, 29], heating samples at 95°C for 5min ruined DMT1 western blot (Figs 3, 4A and 6B) whereas only partially impaired endogenous Fpn1 western blot (Figs 4B and 6A). However, heating samples completely impaired the migration of transfected Fpn1 (untagged) being stuck on the top of the separation gel (Fig 2A). We do not have good explanations for these different outcomes in sample heating between DMT1 and Fpn1 12-TMS proteins and between transfected and endogenous Fpn1 proteins. However, these results alert us to be aware of potentially different effects of sample heating on western blotting of any other SLC transporters and transmembrane proteins. It is therefore important to find the optimum condition of sample preparation for each transmembrane protein western blotting. This was also the case in TfR1 western blotting, in which non-heated samples tended to give rise to stronger and consistent iron status-dependent TfR1 band despite showing the additional TfR1 dimer band (Fig 6D, S2 Fig). In contrast, heating samples was essential for detection of cytoplasmic ferritin H subunit protein in western blotting because ferritin is assembled of 24 subunits of H and L proteins [11]. These results suggest that a single western blot loaded only either heated or non-heated protein samples cannot be used for successive reprobing with DMT1, Fpn1, TfR1, and ferritin antibodies. Another cytoplasmic protein GAPDH, often used as a protein loading control of western blotting, was not affected by heated or unheated protein samples. It should be noted that, although we observed no improvement for Fpn1 western blotting by switching from RIPA to RIPA plus sonication or commercially available membrane protein extraction lysis buffer (Fig 2A), the lysis buffer components together with mechanical destruction of membranes may also significantly improve western blotting for some other transmembrane proteins more than the impact of heating protein samples.

It may be a routine practice for laboratories and researchers primarily working on transmembrane proteins to avoid heat-denaturing protein samples prior to gel loading. Alternatively, they may have additional technical tips for particular transmembrane protein western blotting that we have not tested in this study. Indeed, no sample heating prior to gel loading for Fpn1 western blotting was noted in some earlier publications [22, 26, 28], while we observed relatively few attempts of DMT1 western blotting in earlier publications or no particular notes for western sample preparations except examples such as pre-incubation at 37°C for 15min by Nam et al [45]. CiteAb records more than 50 citations for several applications with the rabbit polyclonal anti-Fpn1 antibody (NBP1-21502, Novus Biologicals) that we used in this study, in which more than 30 publications used this antibody for western blotting. Most of them did not clarify sample heating conditions or heated at 90–100°C, except 75°C for 10min [46] or no heating [39]. Even if protein samples might have been preheated in most of these publications, they might have observed the right size of the endogenous Fpn1 band as we observed in this study (Figs 4B and 6A). CiteAb also lists more than 10 publications for DMT1 western blotting using Proteintech, Abcam, or Novus Biologicals anti-DMT1 antibody, only some of which noted that they treated samples with gentle heating at 37°C for 30min [4749] or 50°C for 15min [50]. Anti-DMT1 antibodies that have different epitopes from our anti-DMT1 antibody (Cell Signaling Technology, near the N-terminus of human DMT1) may also affect the optimum conditions of protein sample preparation for better resolution of western blotting.

Conclusion

In summary, only non-heated protein samples worked for western blotting with the anti-DMT1 (SLC11A2) monoclonal antibody having the epitope near the N-terminus. Non-heated protein samples gave rise to better resolution and/or stronger band signals in western blotting with anti-Fpn1 (SLC40A1) and anti-TfR1 polyclonal antibodies. Three different lysis buffers, three sample loading buffers, or sample sonication we tested did not improve the resolution of DMT1 and Fpn1 western blots. In contrast, only heated protein samples worked for ferritin western blotting with the anti-ferritin H monoclonal antibody, while sample heating did not affect western blotting for another cytoplasmic protein GAPDH frequently used for a protein loading control. Collectively, either heated or unheated samples most critically determined the quality and outcome of transmembrane protein western blotting we tested, suggesting that there should be many similar cases for western blotting of other transmembrane and heat-sensitive proteins.

Supporting information

S1 Fig. Unheated samples compromise ferritin western blotting.

WCLs in RIPA buffer were prepared from SW480 cells treated with 0.1–0.5mM FAC (ferric ammonium citrate), 10 or 25ug/ml cisplatin for 18hr. 20ug of WCLs mixed with 2X SDSPAGE sample loading buffer without heating and 25uM cisplatin WCL without or with heating at 95°C, 5min were subjected to Western blotting with anti-ferritin H antibody, followed by incubation with anti-GAPDH antibody. The arrow indicates the ferritin protein stuck on the top of the separation gel.

(TIFF)

S2 Fig. Comparison in western blotting for iron metabolism proteins between heated and unheated protein samples from HepG2 cells treated with iron.

HepG2 cells were untreated or treated with 100, 250uM FAC, or 25uM DFO for 24hr. Caco-2 cells were untreated or treated with 250uM FAC for 24hr. 30ug of HepG2, Caco-2 WCLs along with 10ug of WCL from HEK293 cells transfected with pCMV or pCVM Fpn1 were heated at 95°C for 5min or not heated (at room temperature). They were subjected to successive western blotting with A) anti-Fpn1, B) anti-DMT1, C) anti-TfR1, D) anti-ferritin H, and E) anti-GAPDH antibodies. The arrow in A) indicates the transfected Fpn1 protein stuck on the top of the separation gel. The asterisk in C) may represent a TfR1 dimer.

(TIFF)

S1 File. Original entire blots for figures.

(PDF)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported in part by P30ES025128 from the National Institute of Environmental Health Sciences to the Center for Human Health and the Environment (CHHE). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Almen MS, Nordstrom KJ, Fredriksson R, Schioth HB. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol. 2009;7:50 Epub 2009/08/15. 10.1186/1741-7007-7-50 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nature reviews Drug discovery. 2015;14(8):543–60. Epub 2015/06/27. 10.1038/nrd4626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Hediger MA, Clemencon B, Burrier RE, Bruford EA. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med. 2013;34(2–3):95–107. Epub 2013/03/20. 10.1016/j.mam.2012.12.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Montalbetti N, Simonin A, Kovacs G, Hediger MA. Mammalian iron transporters: families SLC11 and SLC40. Mol Aspects Med. 2013;34(2–3):270–87. Epub 2013/03/20. 10.1016/j.mam.2013.01.002 . [DOI] [PubMed] [Google Scholar]
  • 5.Zhang Y, Zhang Y, Sun K, Meng Z, Chen L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2019;11(1):1–13. Epub 2018/09/22. 10.1093/jmcb/mjy052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Perland E, Fredriksson R. Classification Systems of Secondary Active Transporters. Trends in pharmacological sciences. 2017;38(3):305–15. Epub 2016/12/13. 10.1016/j.tips.2016.11.008 . [DOI] [PubMed] [Google Scholar]
  • 7.Reddy VS, Shlykov MA, Castillo R, Sun EI, Saier MH Jr. The major facilitator superfamily (MFS) revisited. The FEBS journal. 2012;279(11):2022–35. Epub 2012/03/31. 10.1111/j.1742-4658.2012.08588.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends in biochemical sciences. 2016;41(3):274–86. 10.1016/j.tibs.2015.11.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Knutson MD. Iron transport proteins: Gateways of cellular and systemic iron homeostasis. The Journal of biological chemistry. 2017;292(31):12735–43. Epub 2017/06/16. 10.1074/jbc.R117.786632 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dunn LL, Suryo Rahmanto Y, Richardson DR. Iron uptake and metabolism in the new millennium. Trends in cell biology. 2007;17(2):93–100. Epub 2006/12/30. 10.1016/j.tcb.2006.12.003 . [DOI] [PubMed] [Google Scholar]
  • 11.MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxidants & redox signaling. 2008;10(6):997–1030. 10.1089/ars.2007.1893 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gammella E, Buratti P, Cairo G, Recalcati S. The transferrin receptor: the cellular iron gate. Metallomics: integrated biometal science. 2017;9(10):1367–75. Epub 2017/07/04. 10.1039/c7mt00143f . [DOI] [PubMed] [Google Scholar]
  • 13.Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997;388(6641):482–8. 10.1038/41343 . [DOI] [PubMed] [Google Scholar]
  • 14.Illing AC, Shawki A, Cunningham CL, Mackenzie B. Substrate profile and metal-ion selectivity of human divalent metal-ion transporter-1. The Journal of biological chemistry. 2012;287(36):30485–96. Epub 2012/06/28. 10.1074/jbc.M112.364208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wessling-Resnick M. Nramp1 and Other Transporters Involved in Metal Withholding during Infection. The Journal of biological chemistry. 2015;290(31):18984–90. Epub 2015/06/10. 10.1074/jbc.R115.643973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lane DJ, Bae DH, Merlot AM, Sahni S, Richardson DR. Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients. 2015;7(4):2274–96. Epub 2015/04/04. 10.3390/nu7042274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Fleming RE, Migas MC, Zhou X, Jiang J, Britton RS, Brunt EM, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(6):3143–8. Epub 1999/03/17. 10.1073/pnas.96.6.3143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Galy B, Ferring-Appel D, Kaden S, Grone HJ, Hentze MW. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell metabolism. 2008;7(1):79–85. 10.1016/j.cmet.2007.10.006 . [DOI] [PubMed] [Google Scholar]
  • 19.Hubert N, Hentze MW. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(19):12345–50. Epub 2002/09/05. 10.1073/pnas.192423399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lee PL, Gelbart T, West C, Halloran C, Beutler E. The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms. Blood Cells Mol Dis. 1998;24(2):199–215. Epub 1998/06/27. 10.1006/bcmd.1998.0186 . [DOI] [PubMed] [Google Scholar]
  • 21.Czachorowski M, Lam-Yuk-Tseung S, Cellier M, Gros P. Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009;48(35):8422–34. Epub 2009/07/23. 10.1021/bi900606y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Molecular cell. 2000;5(2):299–309. 10.1016/s1097-2765(00)80425-6 . [DOI] [PubMed] [Google Scholar]
  • 23.Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403(6771):776–81. Epub 2000/02/29. 10.1038/35001596 . [DOI] [PubMed] [Google Scholar]
  • 24.Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. The Journal of biological chemistry. 2000;275(26):19906–12. Epub 2000/04/05. 10.1074/jbc.M000713200 . [DOI] [PubMed] [Google Scholar]
  • 25.Gulec S, Collins JF. Molecular mediators governing iron-copper interactions. Annual review of nutrition. 2014;34:95–116. Epub 2014/07/06. 10.1146/annurev-nutr-071812-161215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(5):1324–8. Epub 2005/01/25. 10.1073/pnas.0409409102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106(12):3979–84. 10.1182/blood-2005-06-2398 . [DOI] [PubMed] [Google Scholar]
  • 28.Rice AE, Mendez MJ, Hokanson CA, Rees DC, Bjorkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. Journal of molecular biology. 2009;386(3):717–32. Epub 2009/01/20. 10.1016/j.jmb.2008.12.063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis. 2005;35(1):33–46. Epub 2005/06/07. 10.1016/j.bcmd.2005.04.005 . [DOI] [PubMed] [Google Scholar]
  • 30.Hepcidin Ganz T., a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–8. Epub 2003/03/29. 10.1182/blood-2003-03-0672 . [DOI] [PubMed] [Google Scholar]
  • 31.Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. The Journal of biological chemistry. 2001;276(11):7806–10. Epub 2000/12/13. 10.1074/jbc.M008922200 . [DOI] [PubMed] [Google Scholar]
  • 32.Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. The Journal of biological chemistry. 2001;276(11):7811–9. Epub 2000/12/13. 10.1074/jbc.M008923200 . [DOI] [PubMed] [Google Scholar]
  • 33.Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annual review of nutrition. 2006;26:323–42. Epub 2006/07/20. 10.1146/annurev.nutr.26.061505.111303 . [DOI] [PubMed] [Google Scholar]
  • 34.Arosio P, Carmona F, Gozzelino R, Maccarinelli F, Poli M. The importance of eukaryotic ferritins in iron handling and cytoprotection. The Biochemical journal. 2015;472(1):1–15. Epub 2015/11/01. 10.1042/BJ20150787 . [DOI] [PubMed] [Google Scholar]
  • 35.Theil EC, Matzapetakis M, Liu X. Ferritins: iron/oxygen biominerals in protein nanocages. J Biol Inorg Chem. 2006;11(7):803–10. 10.1007/s00775-006-0125-6 . [DOI] [PubMed] [Google Scholar]
  • 36.Hashimoto K, Tsuji Y. Arsenic-Induced Activation of the Homeodomain-Interacting Protein Kinase 2 (HIPK2) to cAMP-Response Element Binding Protein (CREB) Axis. Journal of molecular biology. 2017;429(1):64–78. 10.1016/j.jmb.2016.11.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Miyazawa M, Tsuji Y. Evidence for a novel antioxidant function and isoform-specific regulation of the human p66Shc gene. Molecular biology of the cell. 2014;25(13):2116–27. 10.1091/mbc.E13-11-0666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell metabolism. 2009;9(5):461–73. Epub 2009/05/07. 10.1016/j.cmet.2009.03.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Miyazawa M, Bogdan AR, Tsuji Y. Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2. Cell Chem Biol. 2019;26(1):85–97 e4. Epub 2018/11/20. 10.1016/j.chembiol.2018.10.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kuhn LC. Iron regulatory proteins and their role in controlling iron metabolism. Metallomics: integrated biometal science. 2015;7(2):232–43. 10.1039/c4mt00164h . [DOI] [PubMed] [Google Scholar]
  • 41.Hentze MW, Caughman SW, Rouault TA, Barriocanal JG, Dancis A, Harford JB, et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science. 1987;238:1570–3. 10.1126/science.3685996 [DOI] [PubMed] [Google Scholar]
  • 42.Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, Kishi F, et al. Iron-dependent regulation of the divalent metal ion transporter. FEBS letters. 2001;509(2):309–16. 10.1016/s0014-5793(01)03189-1 . [DOI] [PubMed] [Google Scholar]
  • 43.Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3. Epub 2004/10/30. 10.1126/science.1104742 . [DOI] [PubMed] [Google Scholar]
  • 44.Hennigar SR, McClung JP. Hepcidin Attenuates Zinc Efflux in Caco-2 Cells. J Nutr. 2016;146(11):2167–73. Epub 2016/11/03. 10.3945/jn.116.237081 . [DOI] [PubMed] [Google Scholar]
  • 45.Nam H, Wang CY, Zhang L, Zhang W, Hojyo S, Fukada T, et al. ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders. Haematologica. 2013;98(7):1049–57. Epub 2013/01/26. 10.3324/haematol.2012.072314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.McCarthy RC, Sosa JC, Gardeck AM, Baez AS, Lee CH, Wessling-Resnick M. Inflammation-induced iron transport and metabolism by brain microglia. The Journal of biological chemistry. 2018;293(20):7853–63. Epub 2018/04/04. 10.1074/jbc.RA118.001949 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Scheiber IF, Wu Y, Morgan SE, Zhao N. The intestinal metal transporter ZIP14 maintains systemic manganese homeostasis. The Journal of biological chemistry. 2019;294(23):9147–60. Epub 2019/04/28. 10.1074/jbc.RA119.008762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Zhao N, Zhang AS, Wortham AM, Jue S, Knutson MD, Enns CA. The Tumor Suppressor, P53, Decreases the Metal Transporter, ZIP14. Nutrients. 2017;9(12). Epub 2018/01/03. 10.3390/nu9121335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Zhao L, Bartnikas T, Chu X, Klein J, Yun C, Srinivasan S, et al. Hyperglycemia promotes microvillus membrane expression of DMT1 in intestinal epithelial cells in a PKCalpha-dependent manner. FASEB J. 2019;33(3):3549–61. Epub 2018/11/14. 10.1096/fj.201801855R [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Liu C, Zhang CW, Lo SQ, Ang ST, Chew KCM, Yu D, et al. S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2018;38(39):8364–77. Epub 2018/08/15. 10.1523/JNEUROSCI.3262-17.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Fanis Missirlis

13 May 2020

PONE-D-20-06977

Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

PLOS ONE

Dear Dr. Tsuji,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address all comments by reviewers, who are in general supportive of the publication of these results. There are two issues of concern, one related to repetitions/statistics, where I ask the authors for clarity above all. Likewise, there was some concern of the use of photoshop in some of the figures, please read carefully and adhere to PLOS One policy with respect to the images and state that you have done so in your reply.

We would appreciate receiving your revised manuscript by Jun 07 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Fanis Missirlis, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Funding:

This work was supported in part by P30ES025128 from the National Institute of

Environmental Health Sciences to the Center for Human Health and the Environment

(CHHE)."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: N/A

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: PLOS ONE

Transmembrane Protein Western Blotting: Impact of Sample Preparation

Overview: A study investigating the effect of heating vs non-heating of protein samples prior to loading and its subsequent effect on detection of SLC11A2, SLC40A1 and TfR1.

Research groups have previously published SLC11A2 and SLC40A1 Western blots where the protein samples were heated prior to loading. Heating samples did not affect the bands in these studies 1,2.

The author describes in the discussion, research groups have also previously published western blots where the samples were not heated prior to loading. Therefore, I am uncertain about the novelty of this study.

Unfortunately, this was a very confusing paper to follow. The use of 12 cell lines to investigate the effect of heating may have been the reason for this confusion. My advice is to select a few cell lines which are involved in iron metabolism (i.e: Caco-2 and HepG2) and investigate what effect heating vs non-heating has on iron proteins from lysates obtained from these lines. Moreover, it would be useful to see if the effects observed are also present when other commercially available antibodies are used.

Further comments

Methods:

Please include a section about cell culture maintenance.

Please indicate how many days following transfection were the Caco-2 cells used?

Did the authors verify knockdown using qPCR?

Were Caco-2 cells undifferentiated/differentiated when lysed?

Results:

Please include figure captions.

1. Kondaiah P, Aslam MF, Mashurabad PC, Sharp PA, Pullakhandam R. Zinc induces iron uptake and DMT1 expression in Caco-2 cells via a PI3K/IRP2 dependent mechanism. Biochemical Journal. 2019;476(11):1573-1583.

2. Scheers NM, Almgren AB, Sandberg A-S. Proposing a Caco-2/HepG2 cell model for in vitro iron absorption studies. The Journal of nutritional biochemistry. 2014;25(7):710-715.

Reviewer #2: In the present work, Author Yoshiaki Tsuji investigated the impact of sample preparation for an optimal detection by western blotting of specific transmembrane proteins, SLC11A2 (DMT1) and SLC40A1 (ferroportin).

This work is based on initial observation of the Author concerning a mediocre functioning of SLC11A2 and SLC40A1 antibodies in his routine western blotting protocol. In the MS Author nicely and adequately explains, step by step, how specific modifications in sample preparation lead to significant improved western blot resolution for membrane proteins.

As far as technical issue for an optimal study of transmembrane protein is concerned, the MS deals about a subject of great interest and concerns proteins involved in iron metabolism, for which Author’s expertise is well established.

That said I have two minor points to address to the Author:

- Discussion, first page. The sentence beginning with “Given researcher’s troubleshooting discussions…” should be rephrased because it is too long and complex in this present form.

- I understand protocols were tested on different cell lines. Were lysates from primary cell cultures been also tested?

Reviewer #3: The manuscript addresses the question how different sample preparation has major affects on the outcome of Western blotting of several proteins related to iron metabolism. This is a worthy study as it can save many researchers a lot of pain, and improve study-outcomes.

Remarks

The authors relate in the abstract to DMT1 as an iron exporter. In most cases it though functions as an importer, when viewing the cytosol of a cell as “in” and the endosome as a part of internalized “out”. Later in the text DMT1 is termed a “transporter”, which does it more justice.

It would be much clearer to use Fpn and DMT1 throughout the paper, and not label the figures in one way and use in the text the SLC terms, sometimes in full and sometimes shortened e.g. SLC40.

In the text, a reference to fig. 2A is missing.

In Figure 3 B, the evidence for a decrease of DMT1 with increased FAC is weak and the decrease with increased Cisplatin is not convincing at all.

Can you please quantify these graphs and also indicate how often each experiment was repeated.

Indicate the number of times the experiments were repeated throughout the manuscript, best in the legends.

There seems to be a discrepancy between Fpn results in fig. 6a and 4b. Any explanation?

Figure legend 1 has a different format than the other legends, giving lot’s of info on blocking and washes. Could be omitted. Giving these details in materials and methods is enough.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Jul 9;15(7):e0235563. doi: 10.1371/journal.pone.0235563.r002

Author response to Decision Letter 0


17 Jun 2020

Response to Reviewers

Manuscript ID#: PONE-D-20-06977

Manuscript Title: Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

Corresponding Author: Dr. Yoshiaki Tsuji

Reviewer #1

Overview: A study investigating the effect of heating vs non-heating of protein samples prior to loading and its subsequent effect on detection of SLC11A2, SLC40A1 and TfR1. Research groups have previously published SLC11A2 and SLC40A1 Western blots where the protein samples were heated prior to loading. Heating samples did not affect the bands in these studies 1,2. The author describes in the discussion, research groups have also previously published western blots where the samples were not heated prior to loading. Therefore, I am uncertain about the novelty of this study. Unfortunately, this was a very confusing paper to follow. The use of 12 cell lines to investigate the effect of heating may have been the reason for this confusion. My advice is to select a few cell lines which are involved in iron metabolism (i.e: Caco-2 and HepG2) and investigate what effect heating vs non-heating has on iron proteins from lysates obtained from these lines. Moreover, it would be useful to see if the effects observed are also present when other commercially available antibodies are used.

Response: Thank you for very constructive and helpful overview.

First, we have never published SLC11A2 (DMT1) western blotting, retrospectively it was not successful because we routinely heated our samples and failed to detect convincing DMT1 bands.

Second, yes this reviewer is right; we published SLC40A1 (Fpn) western blots using unheated samples in very low Fpn1-expressing cells (Cell Chem. Biol., 26:85-97, 2019).

Third, as this reviewer pointed out, several papers showing DMT1 or Fpn1 western blots (in addition to the reviewer’s ref. 1 and 2) used heated samples (e.g. 100oC 10 min, 90oC 2 min, 75oC 10 min, 37oC 30 min), while most papers did not describe specific conditions for preparation of protein samples (discussed in this manuscript). I feel that some of published western blots for DMT1 (probably Fpn1 also) as well as some other SLC family members may not be accurate (particularly blots without indicating positions of protein size markers) or detected only partial quantities that did not aggregate even after heating, as seen in Figures 4 and 6. Please note that we have the following statement in the discussion (page 24) for PLOS ONE readers: “Indeed, no sample heating prior to gel loading for Fpn1 western blotting was noted in some earlier publications (22, 26, 28), while we observed relatively few attempts of DMT1 western blotting in earlier publications or no particular notes for western sample preparations except examples such as pre-incubation at 37oC for 15 min by Nam et al (44)”.

Forth, all cell lines used in this study, including Caco-2 and HepG2, tightly regulate iron metabolism in response to environmental cues therefore have been used for investigation of the mechanisms of iron transport and storage. We hope that showing our results in all these cell lysates would help more researchers perform DMT1, Fpn1, or other transmembrane protein western blots with specific antibodies used in this study as well as their specific antibodies.

We appreciate all of these reviewer’s important points.

Comment 1.1 Methods: Please include a section about cell culture maintenance.

Response: A new section of “Cell Culture and Maintenance” has been created in the Materials and Methods (page 6).

Comment 1.2 Please indicate how many days following transfection were the Caco-2 cells used?

Response: We have included the experimental timeline in the sub-section of Plasmids, siRNA, and Transfection in the Materials and Methods, page 12).

Comment 1.3 Did the authors verify knockdown using qPCR?

Response: Yes, we verified Fpn1 knockdown in untreated Caco-2 cells in the experiment shown Fig. 5A. The qPCR results (35.3%, p=0.007: Fpn1 mRNA with transfection of siFpn1 compared to siControl) were included in the main text (page 18) without showing the graph in order to stay focus on technical tips in transmembrane western blotting. The qPCR methods and primer sets have been included accordingly in the Materials and methods (page 11).

Comment 1.4 Were Caco-2 cells undifferentiated/differentiated when lysed?

Response: They were undifferentiated. In the revised manuscript, we have added a note that “undifferentiated Caco-2 cells were used in this study” in the “Cell Culture and Maintenance” section (page 6) along with in the main text (page 18). Thank you.

Comment 1.5 Results: Please include figure captions.

Response: Thank you, we have included figure captions in all figures.

1. Kondaiah P, Aslam MF, Mashurabad PC, Sharp PA, Pullakhandam R. Zinc induces iron uptake and DMT1 expression in Caco-2 cells via a PI3K/IRP2 dependent mechanism. Biochemical Journal. 2019;476(11):1573-1583.

2. Scheers NM, Almgren AB, Sandberg A-S. Proposing a Caco-2/HepG2 cell model for in vitro iron absorption studies. The Journal of nutritional biochemistry. 2014;25(7):710-715.

Reviewer #2

In the present work, Author Yoshiaki Tsuji investigated the impact of sample preparation for an optimal detection by western blotting of specific transmembrane proteins, SLC11A2 (DMT1) and SLC40A1 (ferroportin). This work is based on initial observation of the Author concerning a mediocre functioning of SLC11A2 and SLC40A1 antibodies in his routine western blotting protocol. In the MS Author nicely and adequately explains, step by step, how specific modifications in sample preparation lead to significant improved western blot resolution for membrane proteins. As far as technical issue for an optimal study of transmembrane protein is concerned, the MS deals about a subject of great interest and concerns proteins involved in iron metabolism, for which Author’s expertise is well established. That said I have two minor points to address to the Author:

Comment 2.1: Discussion, first page. The sentence beginning with “Given researcher’s troubleshooting discussions…” should be rephrased because it is too long and complex in this present form.

Response: Thank you, I totally agree. In the revised manuscript, it has been divided into two sentences and corrected to “We sometimes encounter researcher’s troubleshooting discussions via internet medias about unsuccessful western blotting for detection of particular transmembrane proteins. Along with our initial failure to detect SLC family iron transporters in this study, we anticipate that…..” (page 22)

Comment 2.2: I understand protocols were tested on different cell lines. Were lysates from primary cell cultures been also tested?

Response: I have not tested primary culture cells. I understand this reviewer’s point that inclusion of primary culture cells would be helpful to more researchers having the transmembrane western problem. I expect that this study will be basically applicable to primary cultures. Readers will first test heating and lysis buffer conditions in their primary culture samples as demonstrated in this study, which hopefully could provide them with solutions or a better idea of further trouble shooting.

Reviewer #3

The manuscript addresses the question how different sample preparation has major affects on the outcome of Western blotting of several proteins related to iron metabolism. This is a worthy study as it can save many researchers a lot of pain, and improve study-outcomes.

Comment 3.1: The authors relate in the abstract to DMT1 as an iron exporter. In most cases it though functions as an importer, when viewing the cytosol of a cell as “in” and the endosome as a part of internalized “out”. Later in the text DMT1 is termed a “transporter”, which does it more justice.

Response: We totally agree with the important point. The abstract has been revised as follows:

transmembrane iron transporter proteins; SLC11A2 (divalent metal transporter 1, DMT1), SLC40A1 (ferroportin 1, Fpn1), and transferrin receptor-1 (TfR1),

Comment 3.2: It would be much clearer to use Fpn and DMT1 throughout the paper, and not label the figures in one way and use in the text the SLC terms, sometimes in full and sometimes shortened e.g. SLC40.

Response: This is another important issue we realized after reading the manuscript carefully. In the revised manuscript, we primarily use Fpn1 and DMT1 rather than SLC40A1 and SLC11A2, respectively. All changes have been yellow-highlighted. Thank you for very helpful suggestions.

Comment 3.3: In the text, a reference to fig. 2A is missing.

Response: We have confirmed a reference to Fig. 2A in the text (page 13).

Comment 3.4: In Figure 3 B, the evidence for a decrease of DMT1 with increased FAC is weak and the decrease with increased Cisplatin is not convincing at all. Can you please quantify these graphs and also indicate how often each experiment was repeated. Indicate the number of times the experiments were repeated throughout the manuscript, best in the legends.

Response: We agree with the point of the small DMT1 expression changes in Fig. 3B (and also Fig. 6B). As 1) the trend of slightly decreased DMT1 expression in response to iron treatment is consistent in Fig. 3B and 6B, and 2) this manuscript primarily focuses on technical tips in transmembrane western blotting, we have just tempered the original statement in the text by adding “slightly” decreased DMT1 protein levels (Fig. 3B) at page 16. The experimental repeats have been indicated in each figure legend.

Comment 3.5: There seems to be a discrepancy between Fpn results in fig. 6a and 4b. Any explanation?

Response: Thank you for paying attention to this point. Although there might be a slight difference between these Fpn1 western blots in Caco-2 cells, the trend was similar; namely, heating samples did not compromise Fpn1 western blotting except for transfected (overexpressed) Fpn1.

Comment 3.6: Figure legend 1 has a different format than the other legends, giving lot’s of info on blocking and washes. Could be omitted. Giving these details in materials and methods is enough.

Response: We agree with simplifying the figure legend 1. As suggested, we have dropped redundant information including blocking and washing procedures.

Attachment

Submitted filename: RESPONSE TO REVIEWERS.docx

Decision Letter 1

Fanis Missirlis

18 Jun 2020

Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

PONE-D-20-06977R1

Dear Dr. Tsuji,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Fanis Missirlis, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Fanis Missirlis

23 Jun 2020

PONE-D-20-06977R1

Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

Dear Dr. Tsuji:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Fanis Missirlis

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Unheated samples compromise ferritin western blotting.

    WCLs in RIPA buffer were prepared from SW480 cells treated with 0.1–0.5mM FAC (ferric ammonium citrate), 10 or 25ug/ml cisplatin for 18hr. 20ug of WCLs mixed with 2X SDSPAGE sample loading buffer without heating and 25uM cisplatin WCL without or with heating at 95°C, 5min were subjected to Western blotting with anti-ferritin H antibody, followed by incubation with anti-GAPDH antibody. The arrow indicates the ferritin protein stuck on the top of the separation gel.

    (TIFF)

    S2 Fig. Comparison in western blotting for iron metabolism proteins between heated and unheated protein samples from HepG2 cells treated with iron.

    HepG2 cells were untreated or treated with 100, 250uM FAC, or 25uM DFO for 24hr. Caco-2 cells were untreated or treated with 250uM FAC for 24hr. 30ug of HepG2, Caco-2 WCLs along with 10ug of WCL from HEK293 cells transfected with pCMV or pCVM Fpn1 were heated at 95°C for 5min or not heated (at room temperature). They were subjected to successive western blotting with A) anti-Fpn1, B) anti-DMT1, C) anti-TfR1, D) anti-ferritin H, and E) anti-GAPDH antibodies. The arrow in A) indicates the transfected Fpn1 protein stuck on the top of the separation gel. The asterisk in C) may represent a TfR1 dimer.

    (TIFF)

    S1 File. Original entire blots for figures.

    (PDF)

    Attachment

    Submitted filename: RESPONSE TO REVIEWERS.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES